Skip to content

Bihar Evaluation of Social Franchising and Telemedicine

Bihar Evaluation of Social Franchising and Telemedicine in India

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01345695
Acronym
BEST
Enrollment
106380
Registered
2011-05-02
Start date
2011-05-31
Completion date
2015-10-31
Last updated
2015-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Pneumonia, Diarrhea, Infantile

Keywords

Childhood diarrhea, childhood pneumonia, telemedicine, cluster, treatment-control trial

Brief summary

This study will conduct an evaluation of the World Health Partners (WHP) private provider project to see if the social franchising and telemedicine project has an impact on health outcomes in treatment vs. control areas. The evaluation will also estimate specific parameters of the WHP program that can be used to maximize financial sustainability and replicability/scalability of the program.

Detailed description

In 2011, World Health Partners (WHP) will launch a large social franchising program of healthcare delivery in Bihar, India, with funding from the Bill and Melinda Gates Foundation (BMGF). The WHP project is particularly innovative in integrating a social franchising delivery model with a telemedicine platform. Although social franchising models of delivery are becoming increasingly common, to our knowledge, none of these efforts has been rigorously evaluated. COHESIVE-India plans to undertake an evaluation of the BMGF-financed WHP project. The overarching focus of the evaluation project (called Bihar Evaluation of Social Franchising and Telemedicine (BEST)) is to provide evidence on the performance and effectiveness of the WHP program. In addition to studying the overall impact and effectiveness of the social franchising and telemedicine program, the evaluation will estimate how the WHP model influences outcomes related to two target diseases of interest to BMGF: childhood diarrhea and childhood pneumonia. The Evaluation Design The core objective of the evaluation is to estimate the causal impact of the WHP program on BMGF target disease outcomes as well as other indicators of its primary health care success. The key design feature of the evaluation is that it relies on the franchisee network model of the WHP program. The evaluation design involves identifying villages in Bihar that have asymmetric digital subscriber line (ADSL) connectivity where WHP is likely to find providers who would participate in the program. The areas surrounding these villages that form catchment areas for providers will be identified; 360 such areas will be randomly sampled from the list and divided into 180 treatment and 180 control areas for implementation of the WHP program. The study also includes a detailed costing component to estimate the costs associated with the target diseases and the benefits from the program intervention. In doing so, the evaluation strategy addresses specific policy-relevant questions about sustainability, affordability, replicability, and future Government support for privately provided healthcare options in Bihar as well as in other parts of India. In addition, COHESIVE-India, with funding from external sources also plans to conduct studies that will provide insights on how to improve the effectiveness of the WHP model, as well as its financial sustainability. These studies include the distribution of vouchers for WHP services to estimate household's willingness to pay for them, as well experiments on financial incentives to learn how to improve the performance of network providers. This evaluation is closely aligned with the objectives of the Government of Bihar to reduce the burden of disease. Through a rigorous evaluation of the WHP program, this study will provide evidence on whether this model of rural health service delivery is efficient and whether it can be scaled up. The stated goals of the WHP program indicate the many potential health and economic benefits to the people of Bihar. The evaluation will provide an empirical and objective assessment of the impact of WHP's effort on quality of care available in rural areas (the program anticipates a significant improvement), increases in access to healthcare providers and improved drug supply, reductions in time lapse between onset of disease and optimal care, as well as reductions in unnecessary healthcare expenditures.

Interventions

None listed

Sponsors

Stanford University
CollaboratorOTHER
University College, London
CollaboratorOTHER
Sambodhi Research and Communication Pvt., Ltd.
CollaboratorUNKNOWN
Public Health Foundation of India (PHFI)
CollaboratorUNKNOWN
Institute of Socio-Economic Research in Development and Democracy (ISERDD)
CollaboratorUNKNOWN
Duke University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Households with children age \< 60 months * Persons with tuberculosis or visceral leishmaniasis * Rural private sector medical providers

Exclusion criteria

* Households without children * Households with children aged \> 60 months

Design outcomes

Primary

MeasureTime frameDescription
Improvements in population based health outcomesBaseline; 3 yearsImprovements in population based health outcomes in the treatment vs. the control areas

Secondary

MeasureTime frameDescription
Improvements in population based health outcomes for childhood diarrheaBaseline; 3 yearsProportion of children with diarrhea in the last two weeks who were treated with zinc
Improvements in population based health outcomes for childhood pneumoniaBaseline; 3 yearsProportion of children with suspected pneumonia in the past two weeks who received a full course of antibiotics (five days)
Cost-effectiveness of the service modelBaseline; 3 yearsThrough micro-experiments, we hope to gain insights on how to improve the cost effectiveness of the WHP model, as well as evaluate its financial sustainability. We will also evaluate whether the are overall improvements in the population level health indicators in the treatment vs. the control areas.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026